Tempest Therapeutics Stock (NASDAQ:TPST)
Previous Close
$6.85
52W Range
$5.36 - $35.23
50D Avg
$6.98
200D Avg
$11.30
Market Cap
$25.41M
Avg Vol (3M)
$116.65K
Beta
-2.33
Div Yield
-
TPST Company Profile
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
TPST Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| ZNTL | Zentalis Pharmaceuticals, Inc. |
| PCSA | Processa Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| SANA | Sana Biotechnology, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| RZLT | Rezolute, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| AKTX | Akari Therapeutics, Plc |
| OLMA | Olema Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| RNXT | RenovoRx, Inc. |
| FBRX | Forte Biosciences, Inc. |